Compare Gilead Sciences, Inc. (GILD) vs KraneShares Hang Seng TECH Index ETF (KTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs KraneShares Hang Seng TECH Index ETF — how do they compare? Gilead Sciences, Inc. trades at $136.32 (market cap $168.35B), while KraneShares Hang Seng TECH Index ETF trades at $13.31. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while KraneShares Hang Seng TECH Index ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, KraneShares Hang Seng TECH Index ETF nearer its low. Which is the better fit depends on your goals.
| GILD | KTEC | |
|---|---|---|
Market Cap | $168.35B | — |
Sector | Health | Sector/Thematic |
52-Week High | $155.80 | $19.51 |
52-Week Low | $110.56 | $12.00 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
KTEC trades at $13.29, down 4.66% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The stock lacks disclosed financial ratios, limiting fundamental clarity. Recent news highlights China's AI competition boosting interest in tech ETFs like KTEC, though specific company financials are not detailed in available data.
The outlook hinges on broader tech ETF trends and AI sector momentum, but risks include reliance on macroeconomic factors and competition. Investment potential is tied to sector performance, with caution advised due to incomplete financial disclosures and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About KraneShares Hang Seng TECH Index ETF
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →
